Accomplishments are evidenced by approved products and an advancing pipeline. Seven marketed and partnered products validate our technology and development approach.
Our collaborative approach to drug development is seen both internally and in successful partnerships. Partners include Novartis, Sandoz, Baxter and GSK.
Our formulation technologies and proprietary devices enable delivery directly to the lungs and underpin the company’s development pipeline.
Know-how and experience fuels innovation. Our experienced teams of scientists focus on developing innovative solutions in all areas of drug development.
Our drug development efforts are focused on bronchopulmonary disease - a high unmet need and growing multi billion market.
Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.
19 Nov 2013
Vectura Group plc - Interim Results for the six months ended 30 September 2013
14 Nov 2013
Bruno Angelici joins the Board of Vectura
30 Sep 2013
Vectura and UCB to collaborate and share expertise in severe inflammatory disease
23 Sep 2013
Ultibro Breezhaler (QVA149) approved in Europe
Our innovative and broad clinical pipeline combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors
View our product pipeline
Annual Report and Accounts for Year Ended 31 March 2013
View online report
Vectura and UCB to collaborate and share expertise in severe inflammatory disease.
Chippenham, UK and Brussels, Belgium - 30 September 2013: Vectura Group plc (LSE: VEC; "Vectura") and UCB (EBR: UCB; "UCB") today announced that they have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease.
Share price details
Berenberg European Conference 2013, Pennyhill Park Hotel and Spa, England
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.